Drug Profile
Research programme: oncolytic virus cancer therapeutics - DNAtrix
Alternative Names: Delta 24 ACT; DNX-2450; MYX-135Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Class Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Haematological malignancies; Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 28 Oct 2020 No recent reports of development identified for research development in Haematological-malignancies in USA (Parenteral)